FDA designates Ariad Pharmaceuticals’ lung cancer drug AP26113 as breakthrough therapy

Bezahlte Schaltung

Ariad Pharmaceuticals announced Thursday that the FDA granted breakthrough therapy status for its experimental tyrosine kinase inhibitor (TKI) AP26113 to treat patients with anaplastic lymphoma kinase positive (ALK+), metastatic non-small-cell lung cancer (NSCLC) who are resistant to Pfizer’s Xalkori (crizotinib). Harvey Berger, chief executive of Ariad, said “we are encouraged by the clinical data on AP26113…particularly in patients whose tumour had spread to the brain.”